News · 26 weeks83-60%
2026-03-012026-08-23
Mix2990d
- Insider12(41%)
- Other10(34%)
- SEC Filings3(10%)
- Earnings2(7%)
- Dividends1(3%)
- Leadership1(3%)
Latest news
25 items- PRQuest Diagnostics to Speak at the Baird 2026 Global Healthcare ConferenceSECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m. Eastern Time. The fireside chat and Q&A session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available w
- PRHumanity Brings Biological Age Analysis to the U.S. Through questhealth.comIndividuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile tests purchased through Quest's consumer-initiated testing platformLONDON, Aug. 25, 2026 /PRNewswire/ -- Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE:DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform. Individuals now have the option to select the
- PRQuest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare ConferenceSECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14, 2026, at 10:00 a.m. Eastern Time. The fireside chat and Q&A session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagnostics.com. In addition, th
- PRQuest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease PathologyTest to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10% indeterminate rate, so more patients can receive an actionable insight SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.
- PRWHOOP Makes Advanced Labs Available Without a Wearable MembershipWHOOP Advanced Labs is now available without a WHOOP membership and includes Galleri®, GRAIL's multi-cancer early detection test. WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first time, making WHOOP Advanced Labs available without a membership. WHOOP Advanced Labs is powered in the U.S. by Quest Diagnostics (NYSE:DGX). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818086969/en/WHOOP Makes Advanced Labs Available Without a Wearable Membership WHOOP Advanced Labs combines comprehensive blood testing, cl
- PRQuest Diagnostics Declares Quarterly Cash DividendSECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026. About Quest DiagnosticsQuest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenue
- PRBacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest DiagnosticsLargest nationally representative study finds 12% of patients positive for bacterial vaginosis are infected with at least one STI, such as chlamydia or gonorrheaSECAUCUS, N.J., July 30, 2026 /PRNewswire/ -- Women who test positive for bacterial vaginosis (BV) were over three times more likely to also test positive for one or more non-viral sexually transmitted infections (STIs) than women who test negative for BV, according to a new Health Trends® study from Quest Diagnostics (NYSE:DGX) and Hologic, Inc. In the largest national study of its kind, scientists at Quest and Hologic analyzed deidentified aggregated laboratory data f
- INSIDERSVP & Chief Commercial Officer Delaney Mark E sold $376,288 worth of shares (1,600 units at $235.18) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 10,335 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.27% to 13,557 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERDirector Carter Robert B increased direct ownership by 0.29% to 3,864 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERDirector Gregg Vicky B was granted 72 shares, increasing direct ownership by 0.39% to 18,386 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.30% to 15,293 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERDirector Main Timothy L increased direct ownership by 0.09% to 22,460 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERExecutive Vice President & CFO Samad Sam was granted 102 shares, increasing direct ownership by 0.31% to 33,478 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERDirector Lassiter Wright Iii increased direct ownership by 0.06% to 10,323 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP & Chief Commercial Officer Delaney Mark E increased direct ownership by 0.29% to 11,935 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- SECSEC Form 10-Q filed by Quest Diagnostics Incorporated10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- SECQuest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- PRQuest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growthSecond quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted diluted EPS of $3.12, up 19.1% from 2025Full year 2026 revenues now expected to be between $11.95 billion and $12.05 billionFull year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25SECAUCUS, N.J., July 23, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.
- PROne in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use PatternsHair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years agoOverall workforce urine drug positivity remained above 4% for more than a decadeHealthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%Fentanyl positivity declines by nearly half in the general U.S. workforceSECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five workers in the general U.S. workforce (19.1%) tested positive for drug use based on an analysis o
- PRQuest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPIAmerican Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRDSECAUCUS, N.J., July 8, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers. Flatiron Health is a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in
- INSIDERSEC Form 4 filed by Director Wentworth Timothy C4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- PRQuest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease TestingAchieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancersSECAUCUS, N.J., June 24, 2026 /PRNewswire/ -- Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.
- SECSEC Form 11-K filed by Quest Diagnostics Incorporated11-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- PRUTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest DiagnosticsPublished in Nature Communications, the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to the three most used oral antibioticsSECAUCUS, N.J., June 18, 2026 /PRNewswire/ -- A common bacterial strain that lives naturally in people's guts can cause a dangerous or deadly infection for some, especially when it becomes multidrug-resistant and causes chronic urinary-tract infections (UTIs) in elderly women. But the extent of its effect on the broader population and its prevalence in the community was not well known – until now. Klebs
DGX FAQ
6 questionsWhat does Quest Diagnostics Incorporated do?
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers...Where does DGX stock trade?
Quest Diagnostics Incorporated (DGX) is listed on NYSE.What sector and industry is DGX in?
Quest Diagnostics Incorporated operates in the Health Care sector, Medical Specialities industry.What are analysts saying about DGX?
Quest Diagnostics Incorporated has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-01-30.What companies are similar to DGX?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare DGX side-by-side with any of them on Quantisnow.How can I track DGX on Quantisnow?
Quantisnow aggregates Quest Diagnostics Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DGX to receive live email and push alerts on every new disclosure.